

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 19, 2007 <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/567,472
				Filing Date	Feb. 7, 2006
				First Named Inventor	DOBROVOLNY, Petr
				Art Unit	1625
				Examiner Name	Aulakh, Charanjit
				Attorney Docket Number	087329-0108
Sheet	1	of	3		

[illegible]

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code ² (if known)			

Examiner Signature	AULACH	Date Considered	10/3/07
-----------------------	--------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CHIC 1553941.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/567,472
			Filing Date	Feb. 7, 2006
Date Submitted: September 19, 2007 (use as many sheets as necessary)			First Named Inventor	DOBROVOLNY, Petr
			Art Unit	1625
Sheet 2 of 3			Examiner Name	Aulakh, Charanjit
			Attorney Docket Number	087329-0108

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
CA	A23	EP74256	11-20-1986	Miyasaka et al.		
CA	A24	EP74770	03-23-1983	Miyasaka et al.		
CA	A25	EP88642	09-14-1983	Miyasaka et al.		
CA	A26	EP154583	09-11-1988	Funck et al.		
CA	A27	EP154584	02-03-1988	Pressaco et al.		
CA	A28	EP51289	04-09-1986	Gelert		
CA	A29	WO96/31513	10-10-1996	Henegar et al.		
CA	A30	WO2004/100897	11-25-2004	Lin et al.		
CA	A31	WO2005/019223	03-03-2005	Dobrovoly		
CA	A32	WO2005/058910	06-30-2005	Dobrovoly		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
CA	A33	"Combination of Irinotecan (CPT-11) and 5-Fluorouracil with an analysis of cellular determinants of drug activity," PAVILLARD et al. Biochemical Pharmacology, vol. 56: 1315-1322, 1998.*	
CA	A34	"Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies," ARMAND, Jean-Pierre et al. Anti-Cancer Drugs 10 (Suppl. 1): S5-S12 (1999).	
CA	A35	"Phase I/II study of escalating dose of CPT-11 in combination with LV5FU2 ("De Gramont" regimen) every 2 weeks in the treatment of colorectal cancer (CRC) after 5-FU failure," DUCREUX, M. et al., Abstract 823, Proc. of Amer. Soc. Clin. Oncol. 16:234a (1997).	
CA	A36	"Phase I study of a weekly schedule of irinotecan (CPT-11), high-dose folinic acid (FA) and 5-fluorouracil (5-FU) as first line chemotherapy (CT) in metastatic colorectal cancer: Final results," VANHOEFER, U. et al., Abstract 779, Proc. of Amer. Soc. Clin. Oncol. 17:202a (1998).	
CA	A37	"Irinotecan (CPT-11) in the treatment of gastrointestinal cancers," NISHIYAMA, M. Japanese J. Chemotherapy 46(8):292-296 (1998).	
CA	A38	"CPT-11 (Irinotecan) and 5-Fluorouracil: a Promising Combination for Therapy of Colorectal Cancer," SALTZ, L., et al. European J. Cancer 32A(Suppl. 3):S24-S31 (1996).	

Examiner Signature	<i>AULAKH</i>	Date Considered	10/3/07
--------------------	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/567,472
				Filing Date	Feb. 7, 2006
Date Submitted: September 19, 2007 (use as many sheets as necessary)				First Named Inventor	DOBROVOLNY, Petr
				Art Unit	1625
Sheet 3 of 3				Examiner Name	Aulakh, Charanjit
				Attorney Docket Number	087329-0108

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
CA	A39	"Phase I/II study of CPT-11 in combination with LV5FU2 (De Gramont-Regimen) every 2 weeks for the treatment of colorectal cancer (CRC) after 5-FU failure," SEITZ, J.F. et al. Abstract 261, Annals of Oncology 9 (Suppl. 2):68 (1998).		
CA	A40	"Phase I study of a weekly schedule of irinotecan (CPT-11) in combination with high-dose folinic acid and 5-fluorouracil as first line chemotherapy in patients with advanced colorectal cancer," VANHOEFER, U. et al. Abstract 967, Proc. of Amer. Soc. Clin. Oncol. 16:272a (1997).		
CA	A41	"Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives. A-Ring-Substituted 7-Ethylcamptothecins and their E-Ring-Modified Water-Soluble Derivatives," YAEHASHI et al. Chemical & Pharmaceutical Bulletin. Vol. 42. No. 12: 2518-2525(1994).		
CA	A42	"Chemical Modification of an Antitumor Camptothecin: Synthesis and Antitumor Activity of 7-C-Substituted Camptothecins," SAWADA et al. Chemical & Pharmaceutical Bulletin. Vol. 39. No. 10: 2574-2580 (1991).		
CA	A43	"Synthesis and Antitumor Activity of A-Ring or E-Lactone Modified Water-Soluble Prodrugs of 20(S)-Camptothecin, Including Development of Irinotecan Hydrochloride Trihydrate," SAWADA et al. Current Pharmaceutical Design. Vol. 1 No. 1: 113-132 (1995).		
CA	A44	Photodegradation reactions of CPT-II, a derivative of camptothecin. I: chemical structure of main degradation products in an aqueous solution," AKIMOTO et al. Drug Stability. Vol. 1 No. 2.: 118-122 (1996).		
CA	A45	"An Efficient Conversion of Camptothecin to 10-Hydroxycamptothecin," WOOD et al. The Journal of Organic Chemistry. Vol. 60. No. 17: 5739-5740 (1995).		
CA	A46	"Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: Carbamate-Linked, Water-Soluble Derivatives of 7-Ethyl-10-hydroxycamptothecin," SAWADA, et al. Chemical & Pharmaceutical Bulletin, Vol. 39. No. 6: 1446-1454 (1991).		
CA	A47	"Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives: A-Ring Modified and 7, 10-Disubstituted Camptothecins," SAWADA et al. Chemical & Pharmaceutical Bulletin, Vol. 39. No. 12: 3183-3188 (1991).		

Examiner Signature	AULAKH	Date Considered	10/3/07
--------------------	--------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.